Keryx Biopharmaceuticals Announces Participation at Two Upcoming Investor Conferences
November 03 2015 - 4:05PM
Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical
company focused on bringing innovative therapies to market for
people with renal disease, today announced that corporate
presentations would be delivered at the following upcoming investor
conferences.
Credit Suisse 24th Annual Healthcare
Conference Presenter: Greg Madison, Chief Executive
Officer Presentation Date: Tuesday, November 10, 2015 Presentation
Time: 10:00 a.m. MST (12:00 p.m. EST)
Stifel 2015 Healthcare
Conference Presenter: Greg Madison, Chief Executive
Officer Presentation Date: Tuesday, November 17, 2015 Presentation
Time: 11:00 a.m. EST
Live audio webcasts of these presentations will be accessible
from Keryx’s website at http://investors.keryx.com within the
Investor Relations section under the “webcasts and presentations”
page. Archived versions of these webcasts will be available for at
least 15 days following the conclusion of the live
presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston,
is focused on bringing innovative therapies to market for patients
with renal disease. In December 2014, the company launched its
first FDA-approved product, Auryxia™ (ferric citrate) for the
control of elevated serum phosphorus levels, or hyperphosphatemia,
in patients with chronic kidney disease (CKD) on dialysis, in the
United States. In January 2014, ferric citrate was approved
for the treatment of patients with all stages of CKD in Japan,
where it is being marketed as Riona® by Keryx's Japanese partner,
Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September
2015, the European Commission granted European market authorization
for Fexeric® (ferric citrate coordination complex) for the control
of hyperphosphatemia in adults with non-dialysis and
dialysis-dependent chronic kidney disease. For more information
about Keryx, please visit www.keryx.com.
KERYX CONTACT:
Lora Pike
Senior Director, Investor Relations
T: 617-466-3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024